SIM, TAE BO,심태보,CHO, HAN NA,조한나,JU, EUN HYE,주은혜,HUR, WOO YOUNG,허우영,YOON, HO JONG,윤호종,SONG, CHI MAN,송치만,SIM, TAE BOKR,CHO, HAN NAKR,JU, EUN HYEKR,HUR, WOO YOUNGKR,YOON, HO JONGKR,SONG, CHI MANKR
申请号：
KR1020160101135
公开号：
KR1018181300000B1
申请日:
2016.08.09
申请国别(地区):
KR
年份:
2018
代理人:
摘要：
The present invention relates to a therapeutic agent of acute myeloid leukemia containing 1,3,7-trisubstituted 3,4-dihydropyrimido[4,5-d]pyrimidine-2(1H)-one compounds as active ingredients. The therapeutic agent has a low activity of inhibiting wild-NRAS and has an activity of inhibiting proliferation with respect to human acute myeloid leukemia strain (OCI-AML3), and has an activity of inhibiting GCK and ACK1 protein kinase at the same time.본 발명은 야생형-NRAS에 대해서는 저해활성이 저조하면서 NRAS 돌연변이 유전자를 가지는 인간 급성골수성백혈병 세포주 (OCI-AML3)에 대한 증식억제 활성을 가지며, GCK 및 ACK1 단백질 키나아제에 대하여 동시에 억제하는 활성을 가지는, 1,3,7-삼치환된 3,4-다이하이드로피리미도[4,5-d]피리미딘-2(1H)-온 화합물이 유효성분으로 포함된 급성골수성백혈병 치료제에 관한 것이다.
